
    
      This program is being offered on a patient by patient basis while phase 3 studies with
      crenolanib are ongoing.

      Institutional Review Board-/Independent Ethics Committee approval must be granted before, The
      experimental intervention will be administered over 28-day cycles. Compassionate use of
      crenolanib will be limited such that it does not interfere with the supply need for phase 3
      studies.

      There must be adequate understanding of the indication for the requested use.
    
  